NCT04543331 BLUESKY, Observational Study
OBservationaL stUdy to Evaluate fluid reSolution and effectiveness in patients receiving Beovu (brolucizumab) under KeY treatment schemes in neovascular age-related macular degeneration.
NCT04079231 BUZZARD, Phase III
A comparative DouBle Masked, Two-Arm, Randomized, MUlticenter, Phase IIIb Study analyZing the Efficacy and Safety of BroluciZumab versus Aflibercept in Patients with Visual ImpaiRment due to Diabetic Macular Edema.
NCT01958918 SALT, Phase IV
A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg Ranibizumab PRN versus 2 mg Aflibercept bimonthly intravitreal injections on central retinal thickness stability till month 6 of treatment and explore functional outcomes up to month 12 in patients with neovascular AMD.
NCT01594281 PRIDE, Phase II
Multicenter randomized open-label three-arms controlled 12 months clinical Proof of Concept Study to evaluate efficacy and safety of Ranibizumab alone or in combination with Laser Photocoagulation vs. Laser Photocoagulation alone in Proliferative Diabetic Retinopathy.
NCT02194803 ORCA, Observational Study
Observation of Treatment Patterns with Lucentis and Real Life Ophthalmic Monitoring, Including Optional OCT in approved indications Collaboration with GRADE (Bonn) and M3 (Münster).
NCT01131585 RELATION, Phase IIIb
A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of Laser Photocoagulation as adjunctive to Ranibizumab intravitreal injections vs. Laser Photocoagulation monotherapy in patients with Visual Impairment due to Diabetic Macular Edema followed by a 12 month follow up period.
NCT02257632 TIDE AMD, Phase IV
A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF Protein Dynamics following monthly intravitreal injections of 0.5 mg Ranibizumab versus 2 mg Aflibercept until study week 12 in patients with Neovascular (Wet) Age-related Macular Degeneration.
NCT02258009 TIDE DME, Phase IV
A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF Protein Dynamics following monthly intravitreal injections of 0.5 mg Ranibizumab versus 2 mg Aflibercept until study week 12 in patients with Visual Impairment due to Diabetic Macular Edema.